CANF Form 6-K notes CF602 erectile dysfunction patent in Brazil

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. submitted a Form 6-K noting that it has furnished a press release as Exhibit 99.1. The press release, dated November 20, 2025, announces that Can-Fite’s CF602 erectile dysfunction treatment has received a notice of patent allowance in Brazil. The first paragraph of this press release is incorporated by reference into several of the company’s existing Form S-8 and Form F-3 registration statements.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of November 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

The first paragraph of the press release attached hereto as Exhibit 99.1 is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On November 20, 2025, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil”. A copy of this press release is furnished herewith as Exhibit 99.1.

1

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated November 20, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 20, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

3

FAQ

What did Can-Fite BioPharma Ltd. (CANF) report in this Form 6-K?

Can-Fite BioPharma Ltd. reported that it issued a press release announcing its CF602 erectile dysfunction treatment received a notice of patent allowance in Brazil, and furnished that release as Exhibit 99.1.

What is CF602 in Can-Fite BioPharma Ltd.'s November 2025 Form 6-K?

CF602 is described as Can-Fite BioPharma Ltd.’s erectile dysfunction treatment, which is the subject of a notice of patent allowance in Brazil mentioned in the attached press release.

Which exhibit accompanies Can-Fite BioPharma Ltd.'s November 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, which is a press release dated November 20, 2025 titled “Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil.”

How is the CF602 press release used in Can-Fite BioPharma Ltd.'s registration statements?

The first paragraph of the CF602 press release is incorporated by reference into Can-Fite BioPharma Ltd.’s Registration Statements on Form S-8 and Form F-3 listed in the Form 6-K, making it part of those filings from the date of the report.

Who signed the November 2025 Form 6-K for Can-Fite BioPharma Ltd.?

The Form 6-K was signed by Motti Farbstein, who is identified as Chief Executive Officer and Chief Financial Officer of Can-Fite BioPharma Ltd.